{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-25-000104","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2025-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.256997+00:00","generated_at":"2026-05-17T01:36:41.226569+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MiMedx Q3 record revenue $114M (+35% YoY); raises FY2025 guidance","bullets":["Q3 net sales $114M, up 35% YoY; GAAP net income $17M, diluted EPS $0.11.","Adjusted EBITDA $35M, 31% of net sales; Wound product sales grew 40%, Surgical 26%.","Cash and equivalents $142M at Sept 30, up from $104M at Dec 31, 2024.","2025 outlook raised: net sales growth mid-to-high teens, adjusted EBITDA margin at least mid-20%.","CEO cites record revenue, cash flow; awaiting final 2026 CMS reimbursement rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-25-000104","json":"https://secwatch.observer/filing/0001376339-25-000104.json","markdown":"https://secwatch.observer/filing/0001376339-25-000104.md","text":"https://secwatch.observer/filing/0001376339-25-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000104/0001376339-25-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000104/mdxg-20251029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:36:41.226569+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}